NCT01925521已完成1 期
A phase1,Randomized,Double-blind,Placebo-controlled,Two-part,Sequential Ascending Single and Multiple Dose Study to Investigate the Safety, Tolerability and the PK and PD Profile of OPS-2071 in Healthy Male Korean Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 96
- 试验地点
- 2
- 主要终点
- Part2 : adverse event, body weight, physical examination, vital sign, electrocardiogram, clinical laboratory test, Bond and Lader visual analogue scale (BL VAS)
研究概览
简要总结
The objective of this trial is to evaluate the safety and tolerability of single and multiple ascending oral doses of OPS-2071 in healthy male Korean
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •The subject is a healthy male Korean aged 21 to 45 years, inclusive.
- •The subject has a body mass index (BMI) range of 18.5 to 25.0 kg/m2, inclusive, and weighs at least 50 kg.
- •The subject provided written, informed consent prior to any clinical study-specific procedures.
- •Male subject and his female spouse/partner who is of childbearing potential must be using highly effective barrier method of contraception starting at screening and continue throughout the clinical study period and for 3 months after final study drug administration.
- •Male subject must not donate sperm starting at screening and throughout the clinical study period and for 3 months after final study drug administration.
排除标准
- •Any clinically significant history of allergic conditions
- •Any history or evidence of any clinically significant disease or as judged by the Investigator.
- •Any clinically significant abnormality after the Investigator's review of the physical examination, ECG and clinical study protocol-defined clinical laboratory tests at screening or admission to the clinical unit.
- •A mean pulse of <45 or >90 beats per minute (bpm) and mean systolic blood pressure (SBP) >140 mmHg; mean diastolic blood pressure (DBP) >90 mmHg
- •A mean QTcB interval >450 ms at screening. If the mean QTcB exceeds the limits above, one additional triplicate ECG may be taken. If this triplicate also gives an abnormal result, the subject should be excluded.
- •Use of any prescribed or non-prescribed drugs in the 2 weeks prior to study drug administration, except for the occasional use of paracetamol (up to 2 g/day).
- •Consumption of grapefruit, pomelo, citrus fruits, starfruit, pomegranate, papaya, mango, rambutan, kiwi fruit, dragon fruit or passion fruit and products containing these fruits in the 2 weeks prior to study drug administration.
- •Excessive use of caffeine-containing beverages exceeding 500 mg caffeine/day (5 cups of coffee) and the inability to refrain from the use of caffeine-containing beverages during confinement in the clinical unit.
- •Current smokers and history of smoking within 3 months prior to screening.
- •History of drinking more than 21 units of alcohol per week (1 unit=10 g pure alcohol=250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) within 3 months prior to the first admission to the clinical unit.
- •Any use of drugs-of-abuse within 3 months prior to the first admission to the clinical unit.
- •Any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days, or donated plasma within 7 days prior to the first admission to the clinical unit.
- •Positive serology test for hepatitis B surface antigen, hepatitis A virus antibodies (immunoglobulin M), hepatitis C virus (HCV) antibodies or human immunodeficiency virus (HIV) 1 and/or 2 antibodies.
- •Participation in any clinical study within 3 months prior to the expected date of enrolment into the clinical study, provided that the clinical study did not entail a biological compound with a longer t½ or participation in more than 3 clinical studies within 12 months.
- •The subject has any other condition, which in the opinion of the Investigator precludes the subject's participation in the clinical study.
- •Employee of the Sponsor or the site.
- •Vulnerable subjects, e.g. subjects kept in detention.
- •Veins unsuitable for repeat venipuncture.
- •Are unlikely to comply with the protocol requirements, instructions and study related restrictions; e.g. uncooperative attitude, inability to return for follow-up visits and improbability of completing the clinical study.
研究组 & 干预措施
Part1 : OPS-2071
Experimental
Single dose, OPS-2071 30,60,120,240,300,600,900,1200mg/day
干预措施: Part1 : OPS-2071 (Drug)
Part1 : Placebo of OPS-2071
Placebo Comparator
Single dose, Placebo
干预措施: Part1 : Placebo of OPS-2071 (Drug)
Part2 : OPS-2071
Experimental
Multiple dose
干预措施: Part2 : OPS-2071 (Drug)
Part2 : Placebo of OPS-2071
Placebo Comparator
Multiple doses, Placebo
干预措施: Part2 : Placebo of OPS-2071 (Drug)
结局指标
主要结局
Part2 : adverse event, body weight, physical examination, vital sign, electrocardiogram, clinical laboratory test, Bond and Lader visual analogue scale (BL VAS)
时间窗: 21days
Bond and Lader VAS: Day -1 and last dosing day (within 1 hour of expected Cmax)
Part1 : adverse event, body weight, physical examination, vital sign, electrocardiogram, clinical laboratory test
时间窗: 4days
次要结局
- Part2 : Plasma Pharmacokinetic parameters of OPS-2071(Day 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours post-morning-dose , Days 2 to 6: pre morning and evening dose, last dosing day: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours post-dose.)
- Part1 : Urine Pharmacokinetic parameter of OPS-2071(Day 1: pre-dose, 0-4, 4-8, 8-12, 12-24, 24-48 and 48-72 hours post-dose)
- Part2 : Urine pharmacokinetic parameter of OPS-2071(Day 1 and last dosing day : pre-morning dose, 0-4 post-morning dose, 4-8 post-morning dose and 8-12 hours post-morning dose.)
- Part1 : Fecal pharmacokinetic parameters of OPS-2071(All post-dose samples)
- Part1 : Plasma pharmacokinetic parameters of OPS-2071(pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 72 hours post-dose)
- Part2 : Microflora test(Pre-dose, last dosing day to the day of discharge,. Day 21)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3Spinocerebellar Ataxia Type 3NCT05160558Biogen8
已完成
1 期
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult ParticipantsHealthy VolunteersNCT03859323Shire104
已完成
1 期
Safety, Tolerability and PK Study of AK0529 in Healthy HumanRespiratory Syncytial Virus InfectionsNCT02297594Shanghai Ark Biopharmaceutical Co., Ltd.74
已完成
1 期
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult ParticipantsHealthy VolunteersNCT04593121Biogen84
已完成
1 期
A Study of LY2940094 in Major Depressive DisorderMajor Depressive DisorderNCT01263236BlackThorn Therapeutics, Inc.66